Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 1 von 2

Details

Autor(en) / Beteiligte
Titel
Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC/ERS 2022 guidelines
Ist Teil von
  • Vascular pharmacology, 2024-06, Vol.155, p.107374-107374, Article 107374
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2024
Link zum Volltext
Quelle
Elsevier ScienceDirect Journals Complete
Beschreibungen/Notizen
  • A comprehensive evaluation of risk, using multiple indices, is necessary to provide reliable prognostic information and guide therapy in pulmonary arterial hypertension (PAH). The current ESC/ERS guidelines suggest using a three-strata model for incident (newly diagnosed) patients and a four-strata model for prevalent patients with PAH. The four-strata model serves as a fundamental risk-stratification tool and relies on a minimal dataset of indicators that must be considered during follow-up. Nevertheless, there are still areas of vagueness and ambiguity when classifying and managing patients in the intermediate-risk category. For these patients, considerations should include right heart imaging, hemodynamics, as well as individual factors such as age, sex, genetic profile, disease type, comorbidities, and kidney function. The aim of this report is to present case studies, with a specific focus on patients ultimately classified as intermediate risk. We aim to emphasize the challenges and complexities encountered in the realms of diagnosis, classification, and treatment for these particular patients. [Display omitted]
Sprache
Englisch
Identifikatoren
ISSN: 1537-1891
eISSN: 1879-3649
DOI: 10.1016/j.vph.2024.107374
Titel-ID: cdi_proquest_miscellaneous_3043069733

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX